Tag: board of directors

Kirk has been a key figure at Armada Hoffler for over 40 years

Basel, Switzerland – June 18, 2025 - TOLREMO therapeutics AG (TOLREMO), a clinical-stage biotechnology company developing TT125-802, a best-in-class CBP/p300 bromodomain inhibitor for the treatment of solid tumors and multiple myeloma, today announced key leadership appointments. Alessandra Cesano, MD, PhD, who has served as Consulting Chief Medical Officer since April 2023, will join the company’s Board of Directors. Florian D. Vogl, MD, PhD, has been appointed as Chief Medical Officer (CMO), succeeding Alessandra Cesano on the executive team.

Cardiff, United Kingdom – 18 June 2025 – Draig Therapeutics (“Draig”), a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, today launches from stealth having raised a total of $140 million (£107 million) in the last nine months. The oversubscribed Series A financing was led by Access Biotechnology, with participation from Canaan Partners, SR One, Sanofi Ventures, Schroders Capital along with seed investors SV Health Investors, which co-founded the company, and ICG.

NEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Pacira BioSciences, Inc. (NASDAQ:PCRX) on behalf of long-term stockholders following a class action complaint that was filed against Pacira on June 16, 2025 with a Class Period from August 2, 2023 – August 8, 2024. Our investigation concerns whether the board of directors of Pacira have breached their fiduciary duties to the company.

BALA CYNWYD, Pa., June 17, 2025 (GLOBE NEWSWIRE) -- Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of AvidXchange Holdings, Inc. (“AvidXchange” or the “Company”) (Nasdaq - AVDX) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to TPG (Nasdaq - TPG). Under the terms of the transaction, TPG will acquire all outstanding shares of AvidXchange common stock for $10.00 per share in a cash transaction that values AvidXchange at $2.2 billion.